NeOnc Technologies Holdings Announces Effectiveness of Registration Statement and Anticipated Listing Date of Common Stock on Nasdaq Global Market
NeOnc Technologies Holdings, a clinical-stage medical biotechnology company, has announced that its registration statement on Form S-1 for a proposed public direct listing has been declared effective by the Securities and Exchange Commission (SEC). The company's common stock is scheduled to begin trading on the Nasdaq Global Market under the ticker symbol 'NTHI' on March 26, 2025.
Interested parties can access the prospectus related to the registration statement through the SEC's EDGAR website or via NeOnc's investor relations page at neonctech.com.
NeOnc Technologies Holdings, un'azienda di biotecnologia medica in fase clinica, ha annunciato che la sua dichiarazione di registrazione sul modulo S-1 per una proposta di quotazione diretta pubblica è stata dichiarata efficace dalla Securities and Exchange Commission (SEC). Le azioni ordinarie dell'azienda sono programmate per iniziare a essere scambiate sul Nasdaq Global Market con il simbolo ticker 'NTHI' il 26 marzo 2025.
Le parti interessate possono accedere al prospetto relativo alla dichiarazione di registrazione attraverso il sito EDGAR della SEC o tramite la pagina delle relazioni con gli investitori di NeOnc su neonctech.com.
NeOnc Technologies Holdings, una empresa de biotecnología médica en etapa clínica, ha anunciado que su declaración de registro en el formulario S-1 para una propuesta de cotización directa pública ha sido declarada efectiva por la Securities and Exchange Commission (SEC). Las acciones ordinarias de la empresa están programadas para comenzar a cotizar en el Nasdaq Global Market bajo el símbolo de cotización 'NTHI' el 26 de marzo de 2025.
Las partes interesadas pueden acceder al prospecto relacionado con la declaración de registro a través del sitio web EDGAR de la SEC o a través de la página de relaciones con inversores de NeOnc en neonctech.com.
NeOnc Technologies Holdings, 임상 단계의 의료 생명공학 회사,는 제안된 공개 직접 상장을 위한 S-1 양식의 등록 성명이 증권 거래 위원회(SEC)에 의해 효력이 발생했다고 발표했습니다. 회사의 보통주는 Nasdaq Global Market에서 'NTHI'라는 티커 기호로 2025년 3월 26일에 거래를 시작할 예정입니다.
관심 있는 당사자는 SEC의 EDGAR 웹사이트 또는 neonctech.com의 NeOnc 투자자 관계 페이지를 통해 등록 성명과 관련된 투자 설명서를 접근할 수 있습니다.
NeOnc Technologies Holdings, une entreprise de biotechnologie médicale en phase clinique, a annoncé que sa déclaration d'enregistrement sur le formulaire S-1 pour une proposition de cotation directe publique a été déclarée effective par la Securities and Exchange Commission (SEC). Les actions ordinaires de l'entreprise devraient commencer à être négociées sur le Nasdaq Global Market sous le symbole ticker 'NTHI' le 26 mars 2025.
Les parties intéressées peuvent accéder au prospectus lié à la déclaration d'enregistrement via le site EDGAR de la SEC ou via la page des relations investisseurs de NeOnc sur neonctech.com.
NeOnc Technologies Holdings, ein biotechnologisches Unternehmen in der klinischen Entwicklungsphase, hat angekündigt, dass seine Registrierungsmitteilung auf dem Formular S-1 für einen vorgeschlagenen öffentlichen Direktlisting von der Securities and Exchange Commission (SEC) für wirksam erklärt wurde. Die Stammaktien des Unternehmens sollen am 26. März 2025 unter dem Tickersymbol 'NTHI' an der Nasdaq Global Market gehandelt werden.
Interessierte Parteien können das Prospekt, das mit der Registrierungsmitteilung verbunden ist, über die EDGAR-Website der SEC oder über die Investor Relations-Seite von NeOnc unter neonctech.com abrufen.
- SEC approval of Form S-1 registration statement
- Upcoming listing on Nasdaq Global Market, providing enhanced visibility and potential liquidity
- Direct listing approach avoiding dilution from traditional IPO
- None.
-- Anticipated Listing March 26, Nasdaq Global Market: Symbol NTHI --
WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (“NeOnc” or the “Company,” to be listed on the NASDAQ Global Market under the symbol: NTHI), a clinical-stage medical biotechnology company, today announced that its registration statement on Form S-1, as filed with the Securities and Exchange Commission (“SEC”), relating to a proposed public direct listing of its common stock, has been declared effective by the SEC. The Company anticipates that its common stock will begin trading on the Nasdaq Global Market under ticker symbol “NTHI” on March 26, 2025.
A copy of the prospectus related to the registration statement may be obtained by visiting EDGAR on the SEC website or via the investor relations page of NeOnc’s website at neonctech.com.
This announcement does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About NeOnc Technologies, Holdings, Inc.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier.
The Company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status.
The Company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California, consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.
For more about NeOnc and its pioneering technology, visit neonctech.com.
Important Cautions Regarding Forward Looking Statements
All statements other than statements of historical facts included in this press release are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Generally, such forward-looking statements include statements regarding our expectations, possible or assumed future actions, business strategies, events, or results of operations, including statements regarding our expectations or predictions or future financial or business performance or conditions and those statements that use forward-looking words such as “projected,” “expect,” “possibility” and “anticipate,” or similar expressions. The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties, and assumptions. Actual results could differ materially from current projections or implied results.
The Company cautions that statements and assumptions made in this news release constitute forward-looking statements without guaranteeing future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management are under no obligation, and expressly disclaim any obligation, to update, alter, or otherwise revise any forward-looking statements following the date of this news release, whether because of new information, future events, or otherwise, except as required by law.
Company Contact:
Patrick Walters
Chief Operations Officer
NeOnc Technologies Holdings, Inc.
info@neonc.com
Investor Relations:
Roger Pondel / Laurie Berman
PondelWilkinson Inc.
(310) 279-5980
rpondel@pondel.com
lberman@pondel.com
FAQ
When will NeOnc Technologies (NTHI) start trading on the Nasdaq Global Market?
What type of listing is NeOnc Technologies (NTHI) pursuing on Nasdaq?
Has the SEC approved NeOnc Technologies' (NTHI) registration statement?
Where can investors find NeOnc Technologies' (NTHI) listing prospectus?
